Trials / Unknown
UnknownNCT04066335
Study to Evaluate the Safety of Nanoxel M Inj.
An Observational Study to Evaluate the Safety of Nanoxel M (Docetaxel-PM) Inj.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,498 (estimated)
- Sponsor
- Samyang Biopharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the safety of Nanoxel M inj. administration in patients.
Detailed description
This is a multi-center, prospective observational study to observe the incidence of adverse events under actual clinical settings to test the safety of Nanoxel-M inj. administration in patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, head \& neck cancer, gastric cancer or esophageal cancer.
Conditions
- Breast Cancer
- Non-small Cell Lung Cancer
- Prostate Cancer
- Ovarian Cancer
- Head and Neck Cancer
- Gastric Cancer
- Esophageal Cancer
Timeline
- Start date
- 2019-09-18
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
- First posted
- 2019-08-26
- Last updated
- 2019-12-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04066335. Inclusion in this directory is not an endorsement.